Floatz logo

Necitumumab

Squamous Cell Lung Cancer

Montefiore Medical Centermonoclonal_antibodyPhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Squamous Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Hospital of Shandong University
Phase 4BBB
Carboplatin
zhang yi
Phase 3BBB
Docetaxel
Shanghai JMT-Bio Inc.
Phase 3BBB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB

View all 45 →

Same molecule, other indications

Necitumumab is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
non-small cell squamous lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Malignant Solid TumorDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →